Research
Hormonal
SGLT2 inhibitors and GLP-1 agonists provide significant cardiovascular and renal protection in Type 2 Diabetes, independent of their glucose-lowering effects.
If you have Type 2 Diabetes and are at risk for heart or kidney problems, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These medications have been shown to protect your heart and kidneys, offering benefits beyond just lowering blood sugar.
StrongSupportsHIGH confidence
The introduction of newer glucose-lowering agents, including sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 agonists, have brought about a paradigm shift in preventing the onset and progression of complications of type 2 diabetes, particularly cardiovascular and renal disease.
Why this rating
Based on multiple large RCTs (EMPA-REG, CANVAS, LEADER, etc.) and meta-analyses.
Source
Preventing diabetes complications
Sophie Templer et al. · Internal Medicine Journal · 2024
DOI 10.1111/imj.16455
narrative_reviewCited 30×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- A multifactorial approach targeting glucose, blood pressure, lipids, and lifestyle simultaneously is the most effective strategy for preventing diabetes complications.Strong
- Intensive glycaemic control reduces microvascular complications (retinopathy, nephropathy, neuropathy) but has limited or potentially harmful effects on macrovascular outcomes and all-cause mortality.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →